Harmony Biosciences Holdings (Harmony Biosciences Holdings) Total Assets : $847.0 Mil (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Harmony Biosciences Holdings Total Assets?

Harmony Biosciences Holdings's Total Assets for the quarter that ended in Mar. 2024 was $847.0 Mil.

During the past 12 months, Harmony Biosciences Holdings's average Total Assets Growth Rate was 27.90% per year. During the past 3 years, the average Total Assets Growth Rate was 32.20% per year. During the past 5 years, the average Total Assets Growth Rate was 111.60% per year.

During the past 6 years, Harmony Biosciences Holdings's highest 3-Year average Total Assets Growth Rate was 225.80%. The lowest was 32.20%. And the median was 62.20%.

Total Assets is connected with ROA %. Harmony Biosciences Holdings's annualized ROA % for the quarter that ended in Mar. 2024 was 18.49%. Total Assets is also linked to Revenue through Asset Turnover. Harmony Biosciences Holdings's Asset Turnover for the quarter that ended in Mar. 2024 was 0.19.

Harmony Biosciences Holdings Total Assets Historical Data

The historical data trend for Harmony Biosciences Holdings's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Harmony Biosciences Holdings Total Assets Chart

Harmony Biosciences Holdings Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Assets

Get a 7-Day Free Trial

106.70

427.07

433.44

673.87

811.45

Harmony Biosciences Holdings Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Assets	Get a 7-Day Free Trial															715.09	760.18	777.77	811.45	846.99

Harmony Biosciences Holdings Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Harmony Biosciences Holdings's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (A: Dec. 2023 )	+	Total Liabilities (A: Dec. 2023 )
	=	466.992	+	344.456
	=	811.4

Harmony Biosciences Holdings's Total Assets for the quarter that ended in Mar. 2024 is calculated as

Total Assets	=	Total Equity (Q: Mar. 2024 )	+	Total Liabilities (Q: Mar. 2024 )
	=	515.394	+	331.591
	=	847.0

Harmony Biosciences Holdings (NAS:HRMY) Total Assets Explanation

Total Assets is connected with ROA %.

Harmony Biosciences Holdings's annualized ROA % for the quarter that ended in Mar. 2024 is

ROA %	=	Net Income (Q: Mar. 2024 )	/	( (Total Assets (Q: Dec. 2023 )	+	Total Assets (Q: Mar. 2024 ))	/ count )
	=	153.336	/	( (811.448	+	846.985)	/ 2 )
	=	153.336	/	829.2165
	=	18.49 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Harmony Biosciences Holdings's Asset Turnover for the quarter that ended in Mar. 2024 is

	Asset Turnover
=	Revenue (Q: Mar. 2024 )	/	( (Total Assets (Q: Dec. 2023 )	+	Total Assets (Q: Mar. 2024 ))	/ count )
=	154.615	/	( (811.448	+	846.985)	/ 2 )
=	154.615	/	829.2165
=	0.19

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Harmony Biosciences Holdings Total Assets Related Terms

Thank you for viewing the detailed overview of Harmony Biosciences Holdings's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Harmony Biosciences Holdings (Harmony Biosciences Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Harmony Biosciences Holdings Inc (NAS:HRMY) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

630 West Germantown Pike, Suite 215, Plymouth Meeting, PA, USA, 19462

Website

https://www.harmonybiosciences.com

Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant), is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and used for the treatment of cataplexy in adult patients with narcolepsy.

Executives

Peter Anastasiou	director	C/O HARMONY BIOSCIENCES HOLDINGS, INC., 630 W. GERMANTOWN PIKE, SUITE 215, PLYMOUTH MEETING PA 19462
Jack Nielsen	director	C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, SUITE 1100, CAMBRIDGE MA 02142
Andreas Wicki	director	C/O HBM BIOVENTURES (CAYMAN) LTD., CENTENNIAL TOWERS,STE.305,2454 W.BAY RD., GRAND CAYMAN E9 E9
Andrew Serafin	officer: Chief Business Officer	630 W. GERMANTOWN PIKE, PLYMOUTH MEETING PA 19462
Jeffrey M. Dayno	officer: Chief Medical Officer	460 EAST SWEDESFORD ROAD, SUITE 1050, WAYNE PA 19087
Jeffrey Dierks	officer: Chief Commercial Officer	630 W. GERMANTOWN PIKE, SUITE 215, PLYMOUTH MEETING PA 19462
John C Jacobs	director, officer: President, CEO	630 W. GERMANTOWN PIKE, SUITE 215, PLYMOUTH MEETING PA 19462
Linda M Szyper	director	C/O NEOS THERAPEUTICS, INC., 2940 N. HIGHWAY 250, SUITE 400, GRAND PRAIRIE TX 75050
Sandip Kapadia	officer: Chief Financial Officer	450 WEST 15 STREET, SUITE 505, NEW YORK NY 10011
R. Mark Graf	director	C/O DISCOVER FINANCIAL SERVICES, 2500 LAKE COOK ROAD, RIVERWOODS IL 60015
Eric L Motley	director	1516 33RD STREET NW, WASHINGTON DC 20007
Valor Equity Partners Iv-a L.p.	10 percent owner	875 NORTH MICHIGAN AVENUE, SUITE 3214, CHICAGO IL 60611
Valor Equity Partners Iv-b L.p.	10 percent owner	875 NORTH MICHIGAN AVENUE, SUITE 3214, CHICAGO IL 60611
Marshman Fund Trust Ii	10 percent owner	630 W. GERMANTOWN PIKE, SUITE 215, PLYMOUTH MEETING PA 19462
Valor Equity Capital Iv Llc	10 percent owner	875 N. MICHIGAN AVENUE, SUITE 3214, CHICAGO IL 60611